|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rihawi K, Ricci AD, Rizzo A, Brocchi S,
Marasco G, Pastore LV, Llimpe FLR, Golfieri R and Renzulli M:
Tumor-associated macrophages and inflammatory microenvironment in
gastric cancer: Novel translational implications. Int J Mol Sci.
22:38052021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Liu C, Peng H, Zhang J and Feng
Q: IL1 receptor antagonist gene IL1-RN variable number of tandem
repeats polymorphism and cancer risk: A literature review and
meta-analysis. PLoS One. 7:e460172012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He J, Hu W, Ouyang Q, Zhang S, He L, Chen
W, Li X and Hu C: Helicobacter pylori infection induces stem
cell-like properties in Correa cascade of gastric cancer. Cancer
Lett. 542:2157642022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mommersteeg MC, Simovic I, Yu B, van
Nieuwenburg SAV, Bruno IMJ, Doukas M, Kuipers EJ, Spaander MCW,
Peppelenbosch MP, Castaño-Rodríguez N and Fuhler GM: Autophagy
mediates ER stress and inflammation in Helicobacter pylori-related
gastric cancer. Gut Microbes. 14:20152382022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molaei F, Forghanifard MM, Fahim Y and
Abbaszadegan MR: Molecular signaling in tumorigenesis of gastric
cancer. Iran Biomed J. 22:217–230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J, Du L and Chen X: Adenosine
signaling: Optimal target for gastric cancer immunotherapy. Front
Immunol. 13:10278382022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Q, Cao T, Zhang X, Hui J, Wang C,
Zhang W, Wang P, Zhou Y and Han S: ATXN2-mediated PI3K/AKT
activation confers gastric cancer chemoresistance and attenuates
CD8+ Tcell cytotoxicity. J Immunol Res. 2022:68632402022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu K, Yuan S, Wang C and Zhu H:
Resistance to immune checkpoint inhibitors in gastric cancer. Front
Pharmacol. 14:12853432023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan I, Kamal A and Akhtar S: Diabetes
driven oncogenesis and anticancer potential of repurposed
antidiabetic drug: A systemic review. Cell Biochem Biophys.
82:1907–1929. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Ye D, Shen P, Liu X, Zhou P, Zhu G,
Xu Y, Fu Y, Li X, Sun J, et al: Mir-20a-5p induced WTX deficiency
promotes gastric cancer progressions through regulating PI3K/AKT
signaling pathway. J Exp Clin Cancer Res. 39:2122020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren
W, Li H, Zhao L, Liu H and Jiao Z: A novel UBE2T inhibitor
suppresses Wnt/β-catenin signaling hyperactivation and gastric
cancer progression by blocking RACK1 ubiquitination. Oncogene.
40:1027–1042. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng W, Zhu J, Zeng D, Guo J, Huang G,
Zeng Y, Wang L, Bin J, Liao Y, Shi M and Liao W: Epigenetic
modification-associated molecular classification of gastric cancer.
Lab Invest. 103:1001702023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen D, Xiong L, Zhang L, Yu H, Xu Y, Wang
M, Jiang X and Xiong Z: CSF1R is a prognostic biomarker and
correlated with immune cell infiltration in the gastric cancer
microenvironment. Pharmgenomics Pers Med. 14:445–457.
2021.PubMed/NCBI
|
|
16
|
van Schooten TS, Derks S, Jiménez-Martí E,
Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M,
Riquelme A, et al: The LEGACy study: A European and Latin American
consortium to identify risk factors and molecular phenotypes in
gastric cancer to improve prevention strategies and personalized
clinical decision making globally. BMC Cancer. 22:6462022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peña-Flores JA, Enríquez-Espinoza D,
Muela-Campos D, Álvarez-Ramírez A, Sáenz A, Barraza-Gómez AA, Bravo
K, Estrada-Macías ME and González-Alvarado K: Functional relevance
of the long intergenic non-coding RNA regulator of reprogramming
(Linc-ROR) in cancer proliferation, metastasis, and drug
resistance. Noncoding RNA. 9:122023.PubMed/NCBI
|
|
18
|
Liu W, Luo M, Zou L, Liu X, Wang R, Tao H,
Wu D, Zhang W, Luo Q and Zhao Y: uNK cell-derived TGF-β1 regulates
the long noncoding RNA MEG3 to control vascular smooth muscle cell
migration and apoptosis in spiral artery remodeling. J Cell
Biochem. 120:15997–16007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye HH, Yang SH and Zhang Y: MEG3 damages
fetal endothelial function induced by gestational diabetes mellitus
via AKT pathway. Eur Rev Med Pharmacol Sci. 22:8553–8560.
2018.PubMed/NCBI
|
|
20
|
Wang X, Li X and Wang Z: lncRNA MEG3
inhibits pituitary tumor development by participating in cell
proliferation, apoptosis and EMT processes. Oncol Rep. 45:402021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Wang Y, Jiang Y, Bai H and Wen Y:
The meaningful function of the emerging clinical targets-lncRNA
MEG3 in gastric cancer. Curr Pharm Des. 29:2204–2212. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo W, Dong Z, Liu S, Qiao Y, Kuang G, Guo
Y, Shen S and Liang J: Promoter hypermethylation-mediated
downregulation of miR-770 and its host gene MEG3, a long non-coding
RNA, in the development of gastric cardia adenocarcinoma. Mol
Carcinog. 56:1924–1934. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li CY, Liang GY, Yao WZ, Sui J, Shen X,
Zhang YQ, Ma SM, Ye YC, Zhang ZY, Zhang WH, et al: Identification
and functional characterization of long non-coding RNAs in human
gastric cancer. Oncol Lett. 15:8805–8815. 2018.PubMed/NCBI
|
|
24
|
Jiao J and Zhang S: Long non-coding RNA
MEG-3 suppresses gastric carcinoma cell growth, invasion and
migration via EMT regulation. Mol Med Rep. 20:2685–2693.
2019.PubMed/NCBI
|
|
25
|
Najafi D, Siri G, Sadri M, Yazdani O,
Esbati R, Karimi P, Keshavarz A, Mehmandar-Oskuie A and Ilktac M:
Combination MEG3 lncRNA and Ciprofloxacin dramatically decreases
cell migration and viability as well as induces apoptosis in GC
cells in vitro. Biotechnol Appl Biochem. 71:809–816. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lüönd F, Sugiyama N, Bill R, Bornes L,
Hager C, Tang F, Santacroce N, Beisel C, Ivanek R, Bürglin T, et
al: Distinct contributions of partial and full EMT to breast cancer
malignancy. Dev Cell. 56:3203–3221. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leung DHL, Phon BWS, Sivalingam M,
Radhakrishnan AK and Kamarudin MNA: Regulation of EMT markers,
extracellular matrix, and associated signalling pathways by long
non-coding RNAs in glioblastoma mesenchymal transition: A scoping
review. Biology (Basel). 12:8182023.PubMed/NCBI
|
|
28
|
Giordo R, Ahmadi FAM, Husaini NA,
Al-Nuaimi NRAM, Ahmad SMS, Pintus G and Zayed H: microRNA 21 and
long non-coding RNAs interplays underlie cancer pathophysiology: A
narrative review. Noncoding RNA Res. 9:831–852. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amini F, Khalaj-Kondori M, Moqadami A and
Rajabi A: Expression of HOTAIR and MEG3 are negatively associated
with H. pylori positive status in gastric cancer patients. Genes
Cancer. 13:1–8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khosroshahi NS, Akbarzadeh S, Abbaslou EM,
Rajabi A, Abdi A, Saber A, Pakmanesh AR and Safaralizadeh R:
Upregulation of lncRNA ANRASSF1 is associated with the lymph node
metastasis and H. pylori infection in gastric cancer. Biomark Med.
19:571–576. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rashwan HH, Taher AM, Hassan HA, Awaji AA,
Kiriacos CJ, Assal RA and Youness RA: Harnessing the supremacy of
MEG3 LncRNA to defeat gastrointestinal malignancies. Pathol Res
Pract. 256:1552232024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu J, Wang X, Zhu C and Wang K: A review
of current evidence about lncRNA MEG3: A tumor suppressor in
multiple cancers. Front Cell Dev Biol. 10:9976332022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Laurentino S, Beygo J, Nordhoff V, Kliesch
S, Wistuba J, Borgmann J, Buiting K, Horsthemke B and Gromoll J:
Epigenetic germline mosaicism in infertile men. Hum Mol Genet.
24:1295–1304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dirks RAM, van Mierlo G, Kerstens HHD,
Bernardo AS, Kobolák J, Bock I, Maruotti J, Pedersen RA, Dinnyés A,
Huynen MA, et al: Allele-specific RNA-seq expression profiling of
imprinted genes in mouse isogenic pluripotent states. Epigenetics
Chromatin. 12:142019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu JL, Meng FM and Li HJ: High expression
of lncRNA MEG3 participates in non-small cell lung cancer by
regulating microRNA-7-5p. Eur Rev Med Pharmacol Sci. 22:5938–5945.
2018.PubMed/NCBI
|
|
36
|
Qiu YY, Wu Y, Lin MJ, Bian T, Xiao YL and
Qin C: LncRNA-MEG3 functions as a competing endogenous RNA to
regulate Treg/Th17 balance in patients with asthma by targeting
microRNA-17/ RORγt. Biomed Pharmacother. 111:386–394. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Uroda T, Anastasakou E, Rossi A, Teulon
JM, Pellequer JL, Annibale P, Pessey O, Inga A, Chillón I and
Marcia M: Conserved Pseudoknots in lncRNA MEG3 are essential for
stimulation of the p53 pathway. Mol Cell. 75:982–995. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang M, Wang F and Zhang X: miRNA-627
inhibits cell proliferation and cell migration, promotes cell
apoptosis in prostate cancer cells through upregulating MAP3K1,
PTPRK and SRA1. Int J Clin Exp Pathol. 11:255–261. 2018.PubMed/NCBI
|
|
39
|
Zhang Y, Wu J, Jing H, Huang G, Sun Z and
Xu S: Long noncoding RNA MEG3 inhibits breast cancer growth via
upregulating endoplasmic reticulum stress and activating NF-κB and
p53. J Cell Biochem. 120:6789–6797. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sannigrahi MK, Sharma R, Panda NK and
Khullar M: Role of non-coding RNAs in head and neck squamous cell
carcinoma: A narrative review. Oral Dis. 24:1417–1427. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu M, Wang X, Gu Y, Wang F, Li L and Qiu
X: MEG3 overexpression inhibits the tumorigenesis of breast cancer
by downregulating miR-21 through the PI3K/Akt pathway. Arch Biochem
Biophys. 661:22–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhan QY, Xie LX and Wang C: Promoting
critical care system and capacity building in pulmonary and
critical care medicine subspecialties. Zhonghua Yi Xue Za Zhi.
103:3149–3151. 2023.(In Chinese). PubMed/NCBI
|
|
43
|
Zamani M, Sadeghizadeh M, Behmanesh M and
Najafi F: Dendrosomal curcumin increases expression of the long
non-coding RNA gene MEG3 via up-regulation of epi-miRs in
hepatocellular cancer. Phytomedicine. 22:961–967. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH
and Guo RH: Decreased expression of long noncoding RNA MEG3 affects
cell proliferation and predicts a poor prognosis in patients with
colorectal cancer. Tumour Biol. 36:4851–4859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu W, Zhou S, Fei G and Wang R: The role
of long noncoding RNA MEG3 in fibrosis diseases. Postgrad Med J.
100:529–538. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dunn-Davies H, Dudnakova T, Nogara A,
Rodor J, Thomas AC, Parish E, Gautier P, Meynert A, Ulitsky I,
Madeddu P, et al: Control of endothelial cell function and
arteriogenesis by MEG3:EZH2 epigenetic regulation of integrin
expression. Mol Ther Nucleic Acids. 35:1021732024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu W, Huang L, Zhang C and Liu Z: lncRNA
MEG3 is downregulated in ankylosing spondylitis and associated with
disease activity, hospitalization time and disease duration. Exp
Ther Med. 17:291–297. 2019.PubMed/NCBI
|
|
48
|
Zheng Q, Lin Z, Xu J, Lu Y, Meng Q, Wang
C, Yang Y, Xin X, Li X, Pu H, et al: Long noncoding RNA MEG3
suppresses liver cancer cells growth through inhibiting β-catenin
by activating PKM2 and inactivating PTEN. Cell Death Dis.
9:2532018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang Y, Tian Z, He L, Meng H, Xie X, Yang
Z, Wang X, Zhao Y and Huang C: RhoGDIβ inhibition via
miR-200c/AUF1/SOX2/miR-137 axis contributed to lncRNA MEG3
downregulation-mediated malignant transformation of human bronchial
epithelial cells. Mol Carcinog. 63:977–990. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng X, Ali MS, Moran M, Viana MP,
Schlichte SL, Zimmerman MC, Khalimonchuk O, Feinberg MW and Sun X:
Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and
insulin signaling by inducing cellular senescence of hepatic
endothelium in obesity. Redox Biol. 40:1018632021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yao H, Duan M, Lin L, Wu C, Fu X, Wang H,
Guo L, Chen W, Huang L, Liu D, et al: TET2 and MEG3 promoter
methylation is associated with acute myeloid leukemia in a Hainan
population. Oncotarget. 8:18337–18347. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yan J, Guo X, Xia J, Shan T, Gu C, Liang
Z, Zhao W and Jin S: MiR-148a regulates MEG3 in gastric cancer by
targeting DNA methyltransferase 1. Med Oncol. 31:8792014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pan T, Ding H, Jin L, Zhang S, Wu D, Pan
W, Dong M, Ma X and Chen Z: DNMT1-mediated demethylation of lncRNA
MEG3 promoter suppressed breast cancer progression by repressing
Notch1 signaling pathway. Cell Cycle. 21:2323–2337. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
McMinn J, Wei M, Schupf N, Cusmai J,
Johnson EB, Smith AC, Weksberg R, Thaker HM and Tycko B: Unbalanced
placental expression of imprinted genes in human intrauterine
growth restriction. Placenta. 27:540–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
El Said NH, Abdrabou W, Mahmood SR, Venit
T, Idaghdour Y and Percipalle P: Nuclear actin-dependent Meg3
expression suppresses metabolic genes by affecting the chromatin
architecture at sites of elevated H3K27 acetylation levels. Nucleic
Acids Res. 53:gkaf2802025. View Article : Google Scholar
|
|
56
|
Luo Y, Wang H, Wang L, Wu W, Zhao J, Li X,
Xiong R, Ding X, Yuan D and Yuan C: LncRNA MEG3: Targeting the
molecular mechanisms and pathogenic causes of metabolic diseases.
Curr Med Chem. 31:6140–6153. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hasenson SE, Alkalay E, Atrash MK,
Boocholez A, Gershbaum J, Hochberg-Laufer H and Shav-Tal Y: The
association of MEG3 lncRNA with nuclear speckles in living cells.
Cells. 11:19422022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ding L, Tian Y, Wang L, Bi M, Teng D and
Hong S: Hypermethylated long noncoding RNA MEG3 promotes the
progression of gastric cancer. Aging (Albany NY). 11:8139–8155.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhou X, Ji G, Ke X, Gu H, Jin W and Zhang
G: MiR-141 inhibits gastric cancer proliferation by interacting
with long noncoding RNA MEG3 and down-regulating E2F3 expression.
Dig Dis Sci. 60:3271–3282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Peng W, Si S, Zhang Q, Li C, Zhao F, Wang
F, Yu J and Ma R: Long non-coding RNA MEG3 functions as a competing
endogenous RNA to regulate gastric cancer progression. J Exp Clin
Cancer Res. 34:792015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cui HB, Ge HE, Wang YS and Bai XY:
MiR-208a enhances cell proliferation and invasion of gastric cancer
by targeting SFRP1 and negatively regulating MEG3. Int J Biochem
Cell Biol. 102:31–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo LL, Song CH, Wang P, Dai LP, Zhang JY
and Wang KJ: Competing endogenous RNA networks and gastric cancer.
World J Gastroenterol. 21:11680–11687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li C, Liang G, Yao W, Sui J, Shen X, Zhang
Y, Ma S, Ye Y, Zhang Z, Zhang W, et al: Differential expression
profiles of long non-coding RNAs reveal potential biomarkers for
identification of human gastric cancer. Oncol Rep. 35:1529–1540.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Soghala S, Harsiny K, Momeni P, Hatami M,
Oskooei VK, Hussen BM, Taheri M and Ghafouri-Fard S:
Down-regulation of LINC-ROR, HOXA-AS2 and MEG3 in gastric cancer.
Heliyon. 8:e111552022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sun M, Xia R, Jin F, Xu T, Liu Z, De W and
Liu X: Downregulated long noncoding RNA MEG3 is associated with
poor prognosis and promotes cell proliferation in gastric cancer.
Tumour Biol. 35:1065–1073. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gao S, Zhao ZY, Wu R, Zhang Y and Zhang
ZY: Prognostic value of long noncoding RNAs in gastric cancer: A
meta-analysis. Onco Targets Ther. 11:4877–4891. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wei GH and Wang X: lncRNA MEG3 inhibit
proliferation and metastasis of gastric cancer via p53 signaling
pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
|
|
68
|
Li Y, Lou S, Zhang J, Zhao S and Lou G:
m6A methylation-mediated regulation of LncRNA MEG3 suppresses
ovarian cancer progression through miR-885-5p and the VASH1
pathway. J Transl Med. 22:1132024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ye M, Lu H, Tang W, Jing T, Chen S, Wei M,
Zhang J, Wang J, Ma J, Ma D and Dong K: Downregulation of MEG3
promotes neuroblastoma development through FOXO1-mediated autophagy
and mTOR-mediated epithelial-mesenchymal transition. Int J Biol
Sci. 16:3050–3061. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
An C, Wang I, Li X, Xia R and Deng F: Long
non-coding RNA in prostate cancer. Am J Clin Exp Urol. 10:170–179.
2022.PubMed/NCBI
|
|
71
|
Ramezani M, Shamsabadi FT and Shahbazi M:
Harnessing the TP53INP1/TP53I3 axis for inhibition of colorectal
cancer cell proliferation through MEG3 and Linc-ROR Co-expression.
Heliyon. 10:e340752024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Dan J, Wang J, Wang Y, Zhu M, Yang X, Peng
Z, Jiang H and Chen L: LncRNA-MEG3 inhibits proliferation and
metastasis by regulating miRNA-21 in gastric cancer. Biomed
Pharmacother. 99:931–938. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Terashima M, Tange S, Ishimura A and
Suzuki T: MEG3 long noncoding RNA contributes to the epigenetic
regulation of epithelial-mesenchymal transition in lung cancer cell
lines. J Biol Chem. 292:82–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li T, Zhang X, Cheng L, Li C, Wu Z, Luo Y,
Zhou K, Li Y, Zhao Q and Huang Y: Modulation of lncRNA H19 enhances
resveratrol-inhibited cancer cell proliferation and migration by
regulating endoplasmic reticulum stress. J Cell Mol Med.
26:2205–2217. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kuai X, Jia L, Yang T, Huang X, Zhao W,
Zhang M, Chen Y, Zhu J, Feng Z and Tang Q: Trop2 promotes multidrug
resistance by regulating Notch1 signaling pathway in gastric cancer
cells. Med Sci Monit. 26:e9195662020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ma Y, Wei X and Wu Z: HNF-4α promotes
multidrug resistance of gastric cancer cells through the modulation
of cell apoptosis. Oncol Lett. 14:6477–6484. 2017.PubMed/NCBI
|
|
77
|
Zhu YX, Yao J, Liu C, Hu HT, Li XM, Ge HM,
Zhou YF, Shan K, Jiang Q and Yan B: Long non-coding RNA MEG3
silencing protects against light-induced retinal degeneration.
Biochem Biophys Res Commun. 496:1236–1242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tu Y, Xie L, Chen L, Yuan Y, Qin B, Wang
K, Zhu Q, Ji N, Zhu M and Guan H: Long non-coding RNA MEG3 promotes
cataractogenesis by upregulating TP53INP1 expression in age-related
cataract. Exp Eye Res. 199:1081852020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang X, Wu N, Wang J and Li Z: LncRNA
MEG3 inhibits cell proliferation and induces apoptosis in laryngeal
cancer via miR-23a/APAF-1 axis. J Cell Mol Med. 23:6708–6719. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu D, Ma Z, Ma D and Li Q: Long non-coding
RNA maternally expressed gene 3 affects cell proliferation,
apoptosis and migration by targeting the microRNA-9-5p/midkine axis
and activating the phosphoinositide-dependent kinase/AKT pathway in
hepatocellular carcinoma. Oncol Lett. 21:3452021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Mitra R, Chen X, Greenawalt EJ, Maulik U,
Jiang W, Zhao Z and Eischen CM: Decoding critical long non-coding
RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat
Commun. 8:16042017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang R, Zou L and Yang X: microRNA-210/
Long non-coding RNA MEG3 axis inhibits trophoblast cell migration
and invasion by suppressing EMT process. Placenta. 109:64–71. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Liu H, Chen C, Zeng J, Zhao Z and Hu Q:
MicroRNA-210-3p is transcriptionally upregulated by hypoxia
induction and thus promoting EMT and chemoresistance in glioma
cells. PLoS One. 16:e02535222021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang Z, Xia P, Hu J, Huang Y, Zhang F, Li
L, Wang E, Guo Q and Ye Z: LncRNA MEG3 alleviates diabetic
cognitive impairments by reducing mitochondrial-derived apoptosis
through promotion of FUNDC1-related mitophagy via Rac1-ROS axis.
ACS Chem Neurosci. 12:2280–2307. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Elimam H, Zaki MB, Abd-Elmawla MA, Darwish
HA, Hatawsh A, Aborehab NM, Mageed SSA, Moussa R, Mohammed OA,
Abdel-Reheim MA and Doghish AS: Natural products and long
non-coding RNAs in prostate cancer: Insights into etiology and
treatment resistance. Naunyn Schmiedebergs Arch Pharmacol.
18:2025.
|
|
86
|
Bai Z, Hu K, Yu J, Shen Y and Chen C:
Macrophage migration inhibitory factor protects bone marrow
mesenchymal stem cells from hypoxia/ischemia-induced apoptosis by
regulating lncRNA MEG3. J Zhejiang Univ Sci B. 23:989–1001. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhu J, Liu S, Ye F, Shen Y, Tie Y, Zhu J,
Wei L, Jin Y, Fu H, Wu Y and Zheng X: Long Noncoding RNA MEG3
interacts with p53 protein and regulates partial p53 target genes
in hepatoma cells. PLoS One. 10:e01397902015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ali MS, Cheng X, Moran M, Haemmig S,
Naldrett MJ, Alvarez S, Feinberg MW and Sun X: LncRNA Meg3 protects
endothelial function by regulating the DNA damage response. Nucleic
Acids Res. 47:1505–1522. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zheng H, Li BH, Liu C, Jia L and Liu FT:
Comprehensive analysis of lncRNA-mediated ceRNA crosstalk and
identification of prognostic biomarkers in Wilms' tumor. Biomed Res
Int. 2020:49516922020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bauer NC, Yang A, Wang X, Zhou Y,
Klibanski A and Soberman RJ: A cross-nearest neighbor/Monte Carlo
algorithm for single-molecule localization microscopy defines
interactions between p53, Mdm2, and MEG3. J Biol Chem.
296:1005402021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Luo Q, Cui M, Deng Q and Liu J:
Comprehensive analysis of differentially expressed profiles and
reconstruction of a competing endogenous RNA network in papillary
renal cell carcinoma. Mol Med Rep. 19:4685–4696. 2019.PubMed/NCBI
|
|
92
|
Kumar S, Williams D, Sur S, Wang JY and Jo
H: Role of flow-sensitive microRNAs and long noncoding RNAs in
vascular dysfunction and atherosclerosis. Vascul Pharmacol.
114:76–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Tan J, Xiang L and Xu G: LncRNA MEG3
suppresses migration and promotes apoptosis by sponging miR-548d-3p
to modulate JAK-STAT pathway in oral squamous cell carcinoma. IUBMB
Life. 71:882–890. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li Y, Zhang L, Zhao Y, Peng H, Zhang N and
Bai W: MEG3 sponges miRNA-376a and YBX1 to regulate angiogenesis in
ovarian cancer endothelial cells. Heliyon. 9:e132042023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang C, Qin Y, Tang Y, Gu M, Li Z and Xu
H: MEG3 in hematologic malignancies: from the role of disease
biomarker to therapeutic target. Pharmacogenet Genomics.
34:209–216. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wei Q, Liu G, Huang Z, Huang Y, Huang L,
Huang Z, Wu X, Wei H and Pu J: LncRNA MEG3 inhibits tumor
progression by modulating macrophage phenotypic polarization via
miR-145-5p/DAB2 axis in hepatocellular carcinoma. J Hepatocell
Carcinoma. 10:1019–1035. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lin J, Huang J, Tan C, Wu S, Lu X and Pu
J: LncRNA MEG3 suppresses hepatocellular carcinoma by stimulating
macrophage M1 polarization and modulating immune system via
inhibiting CSF-1 in vivo/vitro studies. Int J Biol Macromol.
281:1364592024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Huang CY, Chou ST, Hsu YM, Chao WJ, Wu GH,
Hsiao JR, Wang HD and Shiah SG: MEG3-mediated oral
squamous-cell-carcinoma-derived exosomal miR-421 activates
angiogenesis by targeting HS2ST1 in vascular endothelial cells. Int
J Mol Sci. 25:75762024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Kong X, Yang S, Liu C, Tang H, Chen Y,
Zhang X, Zhou Y and Liang G: Relationship between MEG3 gene
polymorphism and risk of gastric cancer in Chinese population with
high incidence of gastric cancer. Biosci Rep. 40:BSR202003052020.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liu H, Ye D, Chen A, Tan D, Zhang W, Jiang
W, Wang M and Zhang X: A pilot study of new promising non-coding
RNA diagnostic biomarkers for early-stage colorectal cancers. Clin
Chem Lab Med. 57:1073–1083. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ghaedi H, Mozaffari MAN, Salehi Z, Ghasemi
H, Zadian SS, Alipoor S, Hadianpour S and Alipoor B: Co-expression
profiling of plasma miRNAs and long noncoding RNAs in gastric
cancer patients. Gene. 687:135–142. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li MK, Liu LX, Zhang WY, Zhan HL, Chen RP,
Feng JL and Wu LF: Long non-coding RNA MEG3 suppresses
epithelial-to-mesenchymal transition by inhibiting the
PSAT1-dependent GSK-3β/Snail signaling pathway in esophageal
squamous cell carcinoma. Oncol Rep. 44:2130–2142. 2020.PubMed/NCBI
|
|
103
|
Li J, Jiang X, Li C, Liu Y, Kang P, Zhong
X and Cui Y: LncRNA-MEG3 inhibits cell proliferation and invasion
by modulating Bmi1/RNF2 in cholangiocarcinoma. J Cell Physiol.
234:22947–22959. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ji Y, Feng G, Hou Y, Yu Y, Wang R and Yuan
H: Long noncoding RNA MEG3 decreases the growth of head and neck
squamous cell carcinoma by regulating the expression of miR-421 and
E-cadherin. Cancer Med. 9:3954–3963. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ning J, Zhang L, Guo H, Zhou S, Sun X and
Bao W: LncRNA MEG3 inhibits the development of nasopharyngeal
carcinoma by sponging miR-543 targeting KLF4. Transl Cancer Res.
9:958–971. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Jin L, Cai Q, Wang S, Wang S, Mondal T,
Wang J and Quan Z: Long noncoding RNA MEG3 regulates LATS2 by
promoting the ubiquitination of EZH2 and inhibits proliferation and
invasion in gallbladder cancer. Cell Death Dis. 9:10172018.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Liu L, Liu Y, Zhang S, Zhang J, Meng Y,
Liu D, Gu L, Zhang Y, Xu L, Zhang Z, et al: Celastrol promotes
apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2.
Acupuncture and Herbal Medicine. 4:92–101. 2024. View Article : Google Scholar
|
|
108
|
Huang D, Tang Z, Pu X, Gao F and Chong L:
A novel cabazitaxel liposomes modified with ginsenoside Rk1 for
cancer targeted therapy. Acupuncture and Herbal Medicine.
4:113–121. 2024. View Article : Google Scholar
|
|
109
|
Zhang L, Zhao F, Li W, Song G, Kasim V and
Wu S: The biological roles and molecular mechanisms of long
non-coding RNA MEG3 in the hallmarks of cancer. Cancers (Basel).
14:60322022. View Article : Google Scholar : PubMed/NCBI
|
